Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Cardiovascular Drugs and Therapy
Published in: Cardiovascular Drugs and Therapy 6/2022

20-01-2022 | Ticagrelor | Editorial

Is Aspirin Loading Before Primary Percutaneous Coronary Intervention for Patients with ST-Elevation Myocardial Infarction Necessary?

Authors: Hiroshi Asanuma, Masafumi Kitakaze

Published in: Cardiovascular Drugs and Therapy | Issue 6/2022

Login to get access

Excerpt

Translating fruitful basic research results into actual clinical application has always been difficult. Nonetheless, this palpable gap between the two fields of science medicine should be overcome by investigating and uncovering factors for the application of basic scientific research. The current study challenges this issue focusing on the field of cardioprotection afforded by ischemic preconditioning or postconditioning. …
Literature
1.
2.
Murry CE, Jennings RB, Reimer KA. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation. 1986;74(5):1124–36.CrossRefPubMed
3.
Zhao ZQ, Corvera JS, Halkos ME, Kerendi F, Wang NP, Guyton RA, et al. Inhibition of myocardial injury by ischemic postconditioning during reperfusion: comparison with ischemic preconditioning. Am J Physiol Heart Circ Physiol. 2003;285(2):H579–88.CrossRefPubMed
4.
Staat P, Rioufol G, Piot C, Cottin Y, Cung TT, L’Huillier I, et al. Postconditioning the human heart. Circulation. 2005;112(14):2143–8.CrossRefPubMed
5.
Yang XC, Liu Y, Wang LF, Cui L, Wang T, Ge YG, et al. Reduction in myocardial infarct size by postconditioning in patients after percutaneous coronary intervention. J Invasive Cardiol. 2007;19(10):424–30.PubMed
6.
Xing Z, Tang L, Huang J, Peng X, Hu X. Effects of ischaemic postconditioning on outcomes of patients with ST-segment elevation myocardial infarction who underwent primary percutaneous coronary intervention: a meta-analysis. BMJ Open. 2019;9(3): e022509.CrossRefPubMedPubMedCentral
7.
Patrono C, Coller B, FitzGerald GA, Hirsh J, Roth G. Platelet-active drugs: the relationships among dose, effectiveness, and side effects: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126(3 Suppl):234S-264S.
8.
O’Gara PT, Kushner FG, Ascheim DD, Casey DE Jr, Chung MK, de Lemos JA, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2013;127(4):e362-425.CrossRefPubMed
9.
Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2018;39(2):119–77.CrossRefPubMed
10.
Sanada S, Asanuma H, Minamino T, Node K, Takashima S, Okuda H, et al. Optimal windows of statin use for immediate infarct limitation: 5′-nucleotidase as another downstream molecule of phosphatidylinositol 3-kinase. Circulation. 2004;110(15):2143–9.CrossRefPubMed
11.
Birnbaum Y, Lin Y, Ye Y, Martinez JD, Huang MH, Lui CY, et al. Aspirin before reperfusion blunts the infarct size limiting effect of atorvastatin. Am J Physiol Heart Circ Physiol. 2007;292(6):H2891–7.CrossRefPubMed
12.
Nanhwan MK, Ling S, Kodakandla M, Nylander S, Ye Y, Birnbaum Y. Chronic treatment with ticagrelor limits myocardial infarct size: an adenosine and cyclooxygenase-2-dependent effect. Arterioscler Thromb Vasc Biol. 2014;34(9):2078–85.CrossRefPubMed
13.
Allahham M, Lerman A, Atar D, Birnbaum Y. Why not dipyridamole: a review of current guidelines and re-evaluation of utility in the modern era. Cardiovasc Drugs Ther. 2021;10:1–8.
14.
15.
Yang XM, Liu Y, Cui L, Yang X, Liu Y, Tandon N, et al. Platelet P2Y12 blockers confer direct postconditioning-like protection in reperfused rabbit hearts. J Cardiovasc Pharmacol Ther. 2013;18(3):251–62.CrossRefPubMed
16.
Dost T. Cardioprotective properties of the platelet P2Y12 receptor inhibitor prasugrel on cardiac ischemia/reperfusion injury. Pharmacol Rep. 2020;72(3):672–9.CrossRefPubMed
17.
Birnbaum Y, Birnbaum GD, Birnbaum I, Nylander S, Ye Y. Ticagrelor and rosuvastatin have additive cardioprotective effects via adenosine. Cardiovasc Drugs Ther. 2016;30(6):539–50.CrossRefPubMed
Metadata
Title
Is Aspirin Loading Before Primary Percutaneous Coronary Intervention for Patients with ST-Elevation Myocardial Infarction Necessary?
Authors
Hiroshi Asanuma
Masafumi Kitakaze
Publication date
20-01-2022
Publisher
Springer US
Published in
Cardiovascular Drugs and Therapy / Issue 6/2022
Print ISSN: 0920-3206
Electronic ISSN: 1573-7241
DOI
https://doi.org/10.1007/s10557-022-07314-2

Other articles of this Issue 6/2022

Cardiovascular Drugs and Therapy 6/2022 Go to the issue

Original Article

Efficacy of Statin Therapy in Patients with Hospital Admission for COVID-19

Invited Review Article

Prolyl Hydroxylase Inhibitors: a New Opportunity in Renal and Myocardial Protection

Original Article

SGLT2 Inhibition by Dapagliflozin Attenuates Diabetic Ketoacidosis in Mice with Type-1 Diabetes

Original Article

HPMC improves protective effects of naringenin and isonicotinamide co-crystals against abdominal aortic aneurysm

Letter to the Editor

Reassessment of Confidence in a Network Meta-analysis of Antidysrhythmic Drugs for Atrial Fibrillation Cardioversion

Correction

Correction to: Real-World Dual Antiplatelet Therapy Following Polymer-Free Sirolimus-Eluting Stent Implantations to Treat Coronary Artery Disease

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits